RxDoctor Payments Data

Mohsin Hisamuddin, MD

Internal Medicine · Marietta, GANPI 1740212240

Payments from drug & device makers

$887in general payments, 2019–2025

Across 64 payments — averaging $13.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$212
  • AbbVie$183
  • AstraZeneca$60
  • Lilly USA, LLC$58
  • GSK$50
  • Pfizer$39
  • plus $285 from 14 others

What the payments were for

  • Food & beverage$887100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$887 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$226,307
Medicare patients
373
Services billed
4,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$141,025
EliquisApixaban139$104,343
MounjaroTirzepatide62$84,493
FarxigaDapagliflozin Propanediol74$70,730
JardianceEmpagliflozin61$64,035
Soliqua 100-33Insulin Glargine/Lixisenatide25$45,176
TrulicityDulaglutide22$38,389
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$32,620
JanuviaSitagliptin Phosphate38$25,561
MyrbetriqMirabegron28$20,625
XareltoRivaroxaban16$12,031
Cyclosporine14$7,444
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,188
Spiriva RespimatTiotropium Bromide12$6,601
Memantine Hcl177$5,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$212$141,02575 claims
Lilly USA, LLCMounjaro, Trulicity$58$122,88384 claims
PfizerEliquis$39$104,343139 claims
AstraZenecaFarxiga$60$70,73074 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$25$45,17625 claims
GSKTrelegy Ellipta$50$32,62036 claims
Astellas Pharma US IncMyrbetriq$21$20,62528 claims
Johnson & JohnsonXarelto$13$12,03116 claims
AbbVieSynthroid$183$2,12534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →